Oct 18, 2024 · Piper Sandler has recently reduced Iovance Biotherapeutics Inc (IOVA) stock to Neutral rating, as announced on July 29, 2024, according to Finviz.Earlier, on November 20, 2023, Goldman had initiated the stock to Buy, setting a price target of $12.